VISEN Pharmaceuticals
Company Profile
Business description
VISEN Pharmaceuticals is a late-stage, near-commercialization biopharmaceutical company focused on providing treatments in selected endocrinology diseases in China. It has one Core Product and two other pipeline drug candidates. Its Core Product, lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency (PGHD), a common short stature in patients aged under 18 caused by insufficient growth hormone. TransCon CNP (navepegritide), one of its key drug candidates, is a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia (ACH), a short-limbed dwarfism that results in severe skeletal complications and comorbidities.
Contact
69 Jiuzhang Road
Suite 3-108, Floor 3, Building B
Hengtai Lixiang Chuangxin Tower
Suzhou
CHNSector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
52
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,741.90 | 26.70 | -0.30% |
CAC 40 | 7,804.87 | 14.60 | 0.19% |
DAX 40 | 24,304.46 | 19.12 | -0.08% |
Dow JONES (US) | 42,762.87 | 443.13 | 1.05% |
FTSE 100 | 8,837.91 | 26.87 | 0.30% |
HKSE | 23,792.54 | 114.43 | -0.48% |
NASDAQ | 19,529.95 | 231.51 | 1.20% |
Nikkei 225 | 37,741.61 | 187.12 | 0.50% |
NZX 50 Index | 12,563.48 | 13.67 | -0.11% |
S&P 500 | 6,000.36 | 61.06 | 1.03% |
S&P/ASX 200 | 8,515.70 | 23.20 | -0.27% |
SSE Composite Index | 3,385.36 | 1.26 | 0.04% |